PPAR‐γ: Its ligand and its regulation by microRNAs

Seiri, Parvaneh; Abi, Abbas; Soukhtanloo, Mohammad

doi:10.1002/jcb.28419

Cited by 16 publications

(9 citation statements)

References 164 publications

(279 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diet-induced obesity and/or IR induce a decline in the expression of PPARγ, with potential relevance in obesity-related cancers. Epigenetic regulation of PPARγ may explain its down-regulation, and several microRNAs have been implicated [33]. MiR-27b, 130b, and 138 are upregulated in obesity.…”

Section: The Role Of Peroxisome Proliferator-activated Receptor Gamma (Pparγ) In Obesity and Cancermentioning

confidence: 99%

MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis

Fodor

Lazăr

Buchman

et al. 2021

IJMS

View full text Add to dashboard Cite

Metabolic syndrome (MetS) represents a cluster of disorders that increase the risk of a plethora of conditions, in particular type two diabetes, cardiovascular diseases, and certain types of cancers. MetS is a complex entity characterized by a chronic inflammatory state that implies dysregulations of adipokins and proinflammatory cytokins together with hormonal and growth factors imbalances. Of great interest is the implication of microRNA (miRNA, miR), non-coding RNA, in cancer genesis, progression, and metastasis. The adipose tissue serves as an important source of miRs, which represent a novel class of adipokines, that play a crucial role in carcinogenesis. Altered miRs secretion in the adipose tissue, in the context of MetS, might explain their implication in the oncogenesis. The interplay between miRs expressed in adipose tissue, their dysregulation and cancer pathogenesis are still intriguing, taking into consideration the fact that miRNAs show both carcinogenic and tumor suppressor effects. The aim of our review was to discuss the latest publications concerning the implication of miRs dysregulation in MetS and their significance in tumoral signaling pathways. Furthermore, we emphasized the role of miRNAs as potential target therapies and their implication in cancer progression and metastasis.

show abstract

Section: The Role Of Peroxisome Proliferator-activated Receptor Gamma (Pparγ) In Obesity and Cancermentioning

confidence: 99%

MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis

Fodor

Lazăr

Buchman

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Agonists of this receptor are a therapeutic option in the treatment of patients with diabetes. Current research provides evidence that stimulation of PPARγ receptors inhibits cell proliferation, vessel formation, and induces apoptosis ( Figure 3) [42,43]. These properties make PPARγ agonists attractive candidates for anti-cancer drugs.…”

Section: Ppar: Peroxisome Proliferator-activated Receptorsmentioning

confidence: 99%

Important players in carcinogenesis as potential targets in cancer therapy: an update

2020

View full text Add to dashboard Cite

The development of cancer is a problem that has accompanied mankind for years. The growing number of cases, emerging drug resistance, and the need to reduce the serious side effects of pharmacotherapy are forcing scientists to better understand the complex mechanisms responsible for the initiation, promotion, and progression of the disease. This paper discusses the modulation of the particular stages of carcinogenesis by selected physiological factors, including: acetylcholine (ACh), peroxisome proliferator-activated receptors (PPAR), fatty acid-binding proteins (FABPs), Bruton's tyrosine kinase (Btk), aquaporins (AQPs), insulin-like growth factor-2 (IGF-2), and exosomes. Understanding their role may contribute to the development of more effective and safer therapies based on new binding sites.

show abstract

“…PPARs were originally identified in 1990 with the first cloning (PPARα) happening during molecular targeting for peroxisome proliferating agents in rodents (Issemann and Green, 1990). Since then, several fatty acids and by-products, including eicosanoids, have been identified as PPARs ligands and have also been shown to target many synthetic compounds currently used to treat diabetes and dyslipidaemias, such as thiazolidineodiones (TZDs), including pioglitazone and rosiglitazone, and fibrates (clofibrate) (Guan and Breyer, 2001; Seiri et al, 2019). Therefore, the knowledge of the molecular structure and physiological effects of these receptors becomes particularly important, both in the development and in the use of drugs to treat of metabolic diseases and others illness.…”

Section: Peroxisome Proliferator-activated Receptorsmentioning

confidence: 99%

“…There is a small region in the domain D that connects the DBD to the ligand-binding domain (LBD), or E domain, which is known as the hinge, allowing the rotation of the DBD in relation to the LBD (Guan and Breyer, 2001). The LDB domain is in the carboxy-terminal region and has several functions such as ligand recognition and homo and heterodimerisation of the receptor (Seiri et al, 2019). In addition to these functions, LBD contains a surface that is critical for transcriptional activation.…”

Section: Peroxisome Proliferator-activated Receptorsmentioning

confidence: 99%

“…In addition to these functions, LBD contains a surface that is critical for transcriptional activation. After the activation of this region, called activation function 2 (AF-2), interaction with the co-activators occurs, which will allow the formation of the protein complex involved in the activation of the transcription (Guan and Breyer, 2001; Seiri et al, 2019).…”

Section: Peroxisome Proliferator-activated Receptorsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool

et al. 2019

View full text Add to dashboard Cite

Chemotherapy-induced neuropathic pain (CINP) is one of the most severe side effects of anticancer agents, such as platinum-and taxanes-derived drugs (oxaliplatin, cisplatin, carboplatin and paclitaxel). CINP may even be a factor of interruption of treatment and consequently increasing the risk of death. Besides that, it is important to take into consideration that the incidence of cancer is increasing worldwide, including colorectal, gastric, lung, cervical, ovary and breast cancers, all treated with the aforementioned drugs, justifying the concern of the medical community about the patient's quality of life. Several physiopathological mechanisms have already been described for CINP, such as changes in axonal transport, mitochondrial damage, increased ion channel activity and inflammation in the central nervous system (CNS). Another less frequent event that may occur after chemotherapy, particularly under oxaliplatin treatment, is the central neurotoxicity leading to disorders such as mental confusion, catatonia, hyporeflexia, etc. To date, no pharmacological therapy has shown satisfactory effect in these cases. In this scenario, duloxetine is the only drug currently in clinical use. Peroxisome proliferator-activated receptors (PPARs) belong to the class of nuclear receptors and are present in several tissues, mainly participating in lipid and glucose metabolism and inflammatory response. There are three PPAR isoforms: α, β/δ and γ. PPARγ, the protagonist of this review, is expressed in adipose tissue, large intestine, spleen and neutrophils. This subtype also plays important role in energy balance, lipid biosynthesis and adipogenesis. The effects of PPARγ agonists, known for their positive activity on type II diabetes mellitus, have been explored and present promising effects in the control of neuropathic pain, including CINP, and also cancer. This review focuses largely on the mechanisms involved in chemotherapy-induced neuropathy and the effects of the activation of PPARγ to treat CINP. It is the aim of this review to help understanding and developing novel CINP therapeutic strategies integrating PPARγ signalling.

show abstract

PPAR‐γ: Its ligand and its regulation by microRNAs

Cited by 16 publications

References 164 publications

MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis

MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis

Important players in carcinogenesis as potential targets in cancer therapy: an update

Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool

Contact Info

Product

Resources

About